Pharmacokinetics in nonhuman primates of a prototype carbapenem active against methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 795-798

  Sundelof, J G ^a   Thompson, R ^a   White, K M ^a   Sasor, M W ^a   Cama, L ^a   Kropp, H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; L 695256; PROBENECID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RHESUS MONKEY; STAPHYLOCOCCUS AUREUS;

EID: 0029865681     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.795     Document Type: Article

References (19)

1. Boxenbaum, H. G., S. Riegelman, and R. M. Elashoff. 1974. Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharma. 2:123-148.
2. Chambers, H. F. 1995. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob. Agents Chemother 39:462-466.
3. Curry, S. H. 1980 Drug disposition and pharmacokinetics, 3rd ed., p. 187-194. Blackwell Scientific Publications Ltd., Oxford.
4. de Lencastre, H., and A. Tomasz. 1994. Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2590-2598
5. Hammond, G. G., K. M. Overbye, and L. L. Silver. 1994. Binding of L-695,256, a prototypical 2-aryl carbapenem antibiotic, to penicillin binding proteins of methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus lurae, abstr F62, p. 127. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
6. Huber, J., B. Pelak, K. Dorso, L. Gerckens, E. St. Rose, J. Kohler, S. Dufresue, J. Kahan, D. Shungu, and H. Kropp. 1994. Antimicrobial profile of L-695,256: the prototype MRS-active 2-aryl carbapenem antibiotic, abstr. F54, p. 126. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D C.
7. Johnson, A. P., A. H. C. Uttley, N. Woodford, and R. C. George. 1990. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol Rev. 3:280-291.
8. Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. 1983 Thienamycin. development of imipenem-cilastatin. J. Antimicrob. Chemother. 12 (Suppl. D):1-35.
9. Kath, G., W. McKeel, and J. Sundelof. 1993. Bacterial zone measurement apparatus. Meas Sci. Technol. 4:231-233.
10. Kohler, J., J. Huber, E. St. Rose, K. Dorso, J. Kahan, L. Silver, and H. Kropp. 1994. Lack of stable resistance selection by an anti methicillin-resistant Staphylococcus prototype 2-aryl carbapenem antibiotic, L-695,256, abstr. F60, p 127 In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C
11. Kropp, H., J. G. Sundelof, R. Hajdu, and F. M. Kahan. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. 22:62-70.
12. Lyon, B. R., and R. Skurray. 1987. Antimicrobial resistance of Staphylococcus aureus: genetic basis. Microbiol. Rev. 51:88-134.
13. Malanoski, G., L. Collins, C. T. Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 1994. Comparative in vitro activity of L-695,256, a novel carbapenem, abstr F52, p 126. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Reviews of Infectious Diseases. 1985. Imipenem: the first thienamycin antibiotic. Rev. Infect Dis. 7(Suppl 3):S435-S512
15. Rylander, M., J. Rollof, and S. R. Norrby. 1994. In vitro activity of L-695,256, a carbapenem active against multiply resistant gram-positives, abstr. F56, p. 126. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D C
16. Sasor, M., L. Cama, M. L. Greenlee, F. P. DiNinno, and J. V. Heck. 1994. The synthesis and structure-activity relationships of a series of 2-fluorenonyl carbapenems with excellent activity against MRSA, abstr F50, p. 126 In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Sundelof, J. G., J. J. Jackson, C. J. Gill, W. J. Cleare, N. Walker, K. M. White, and H. Kropp. 1994. In vivo activity of a prototype carbapenem antibiotic in localized and systemic MRSA murine models, abstr. F64, p. 127. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Synergy Software. 1994. KaleidaGraph. Version 3.0.4. Data analysis/graphics application for the Macintosh series of personal computers. Synergy Software, Reading, Pa.
19. Walsh, C. T. 1993. Vancomycin resistance: decoding the molecular logic Science 261:308-309.